AUGX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.88%, SMA50 2.35%, SMA200 -21.41%). The stock’s 14-day RSI is 74.07 (overbought), while the ATR of 0.02 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -62.4% below its high and over 221.92% above its low.

Augmedix, Inc. generated EPS of -$0.47 over the past year. Five-year average earnings growth is 62.58%. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at -$0.17. Next year's EPS is expected at $14.36. Augmedix, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2024, missed forecasts by -33.33%. The prior quarter beat by 31.9%. Over the last six quarters, Apple has recorded several small beats. These include -16.67% in November 06, 2023.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Augmedix, Inc. has 49.43 million shares outstanding. The public float is 24.99 million shares, elevated short interest at 4.02% of float. This equals 1.07 million shares. The short ratio is 5.73 days. Institutional investors hold 86.08% of the float. Insiders own 1.5%. Redmile Group, LLC holds 9.45 million shares, DCM VI, L.P. has 4.17 million shares and Krikorian Jason has 4.17 million shares.

Our AI price prediction model suggests that Augmedix, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.85%, with price expected at $2.37 by October 16, 2024, within a range of $2.35 to $2.39 3-Month Outlook: Projected rise of 246.38%, reaching $8.14 by December 31, 2024, with a range of $7.87 to $8.75. 1-Year Outlook: Projected loss of -46.81%, with price at $1.25 by October 02, 2025, within a range of $0.00 to $0.00.

Augmedix, Inc. (NASDAQ:AUGX) shares are down -59.83% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Augmedix, Inc. trading at a premium to the broader market with a P/E of -5.38. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.50, suggesting 134.04% upside. Our AI forecast model points to short-term strength (0.85% over two weeks), a medium-term rise (246.38% over three months), and a longer-term loss (-46.81% over one year), with expected trading ranges indicating moderate volatility.

The stock is currently mid-range between its 52-week high and low $0.73 and $6.25. With a market capitalization of about $115.91 million, Augmedix, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.19). Key stats such as the average daily volume over the past year has been around 808.77 thousand shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Augmedix, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Emmanuel Krakaris, the company employs approximately 1,430 people and listed since March 31, 2021. Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States.

Augmedix, Inc. trades at a P/E ratio of -5.38, slightly below the S&P 500 average, with a price-to-sales ratio of 2.58 and a price-to-book ratio of 4.42 trading at moderately above to book value. The P/FCF stands at -6.25, also below market averages.